Weight-gain Independent Effect of Mirtazapine on Fasting Plasma Lipids in Healthy Men

doi:10.21203/rs.3.rs-1638623/v1

Download PDF

Research Article

Weight-gain Independent Effect of Mirtazapine on Fasting Plasma Lipids in Healthy Men

https://doi.org/10.21203/rs.3.rs-1638623/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Introduction

Treatment with mirtazapine, a widely prescribed antidepressant, has been linked to weight gain and dyslipidemia. Whether dyslipidemia occurs secondary to increased appetite due to antidepressant treatment, or due to direct pharmacological effects of mirtazapine is unknown.

Methods

The aim of this analysis is to complement our previously published results of the effect of mirtazapine on metabolism and energy substrate partitioning from a proof-of-concept, open-label clinical study (ClinicalTrials.gov NCT00878540) in 12 healthy males (20-25 years). We report the effect of a seven-day administration of mirtazapine 30 mg per day on weight and lipid metabolism in healthy men under highly standardized conditions with respect to diet, physical activity and day-night-rhythm and under continuous clinical observation.

Results

After a seven-day administration of mirtazapine 30 mg, we observed a statistically significant increase in triglyceride levels (mean change +4.4mg/dl;95%CI[-11.4, 2.6];p=0.044) as well as TG/HDL-C ratio (mean change +0.2;95%CI[-0.4, -0.1];p=0.019) and a decrease in HDL-cholesterol (mean change -4.3mg/dl;95%CI[2.1, 6.5];p=0.004), LDL-cholesterol (mean change -8.7mg/dl;95% CI[3.8, 13.5];p=0.008), total cholesterol (mean change -12.3mg/dl;95%CI[5.4, 19.1];p=0.005), and non-HDL-C (mean change -8.0mg/dl;95%CI[1.9, 14.0];p=0.023). Notably, weight (mean change -0.6kg;95%CI[0.4, 0.8];p=0.002) and BMI (mean change -0.2;95%CI[0.1, 0.2];p=0.002) significantly decreased. No change in waist circumference (mean change -0.4cm;95%CI[-2.1;2.9];p=0.838) or waist-to-hip-ratio (mean change 0.0;95%CI[-0.0, 0.0];p=0.814) was observed.

Discussion

This is the first study showing unfavorable changes in lipid metabolism under mirtazapine in healthy individuals despite highly standardized conditions including dietary restriction, and despite the observation of a decrease of weight. Our findings support the hypothesis that mirtazapine has direct pharmacological effects on lipid metabolism.

TRIAL REGISTRATION. ClinicalTrials.gov NCT00878540.

Mirtazapine

Atherogenic Dyslipidemia

TG/HDL-C ratio

Body Weight

Cardiovascular Risk

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) that is widely used in the treatment of major depressive disorder. [1] Its antidepressant effect is mainly attributed to enhanced noradrenergic and serotonergic (5-HT₁-mediated) activity. [2] Mirtazapine acts as an antagonist at central α₂-adrenergic auto- and heteroreceptors and at postsynaptic 5-HT₂- and 5-HT₃- receptors. [3] It has no significant influence on dopamine metabolism but acts as a strong antagonist at histamine H₁-receptors. As histamine plays a central role in appetite regulation, H₁-receptor antagonism may account for adverse effects during treatment with mirtazapine such as weight gain. [1]

Patients treated with mirtazapine frequently report adverse drug effects, most frequently weight gain and sedation. [4-9] Weight gain may, beyond limiting adherence, result in metabolic dysregulation, which aligns with the observation that pharmacotherapy with mirtazapine is associated with dyslipidemia. [7,10,11] Regarding dyslipidemia, treatment with mirtazapine is most consistently associated with a rise in triglycerides. [7] Hypertriglyceridemia being a causal risk factor for atherosclerosis that shows a dose-dependent association to atherosclerotic cardiovascular disease (ASCVD) [12] raises possible concerns about the cardiovascular safety of mirtazapine. The effects of mirtazapine on total cholesterol (TC), LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) are heterogeneous. [7,13,14]

While previous data on the effect of mirtazapine on glucose tolerance in psychiatric patients have been conflicting [15-17], our recent analysis in healthy men revealed a shift in energy substrate partitioning towards carbohydrate substrate preference assessed by indirect calorimetry under highly standardized conditions including dietary restriction. [10] Further, insulin and C-peptide release increased in response to a standardized meal suggesting weight-gain independent, direct pharmacological effects of mirtazapine. [10]

Dyslipidemia, and hypertriglyceridemia in particular, are highly responsive to variables such as diet, changes in body weight, insulin sensitivity and sympathetic tone. [18] Changes in lipid metabolism during treatment with mirtazapine have been accompanied by an increase in body weight in prior studies – often interpreted as a result of increased appetite and changed eating behavior induced by the drug. [7,9] Nevertheless, possible direct effects of mirtazapine on hepatic lipid metabolism independent of weight-gain have not yet been investigated under standardized conditions and biological mechanisms of mirtazapine-associated dyslipidemia remain unclear.

Thus, we investigated the effect of mirtazapine 30 mg daily administered over seven days on weight and fasting plasma lipid profiles in healthy individuals in a highly standardized setting with regard to nutrition, exercise and sleep-wake-rhythm. This analysis complements our previously published findings of the effects of mirtazapine on glucose metabolism and energy substrate partitioning. [10]

Study Design

The study followed a prospective, non-randomized design (ClinicalTrials.gov NCT00878540) involving a homogenous and comprehensively characterized cohort of 12 healthy male volunteers of European ancestry aged 20 to 25 years to study the effect of a seven-day exposure to mirtazapine 30 mg daily on lipid metabolism in a highly standardized setting. Volunteers were recruited via postings at university bulletin boards and through ads on the website of the Max-Planck-Institute. Prior to the initiation of any study related procedures, all study participants gave written informed consent. The study design has been published [10] and is shown in Figure 1. While in previous analysis two participants needed to be excluded due to protocol violation related to the calorimetry, the current analysis was not affected hereby and we report on the full data set of 12 individuals. All study participants were allocated to a standardized three-week ambulatory accommodation phase. Caloric need was individually determined based on age, weight, height and basal metabolic rate as assessed by indirect calorimetry by a registered dietician according to the recommendations of the German Nutrition Society (www.dge.de). Caloric intake was then kept constant throughout the study period, as was physical activity and sleep-wake rhythm. Besides water, any additional drinks were prohibited, as was any additional food. During the ten-day experimental phase, participants were under continuous clinical observation, maintained standardized diet, sleep-wake cycle, and physical activity regimen (two hours of light walking per day, no exercise training). After a three-day adaptation period to the hospital setting, 30 mg mirtazapine was given (Remergil SolTab, Organon) at 10 pm daily for seven days. Compliance was ensured by the presence of qualified study staff during administration of the medication and by measurement of mirtazapine plasma levels. Time spent in bed was standardized (11:00 p.m. to 07:00 a.m.) during the entire study period (preparatory phase and experimental phase).

Study population

Participants were eligible for the study if they were healthy males of European ancestry between 18 and 25 years of age with normal BMI (18.5 - 25 kg/m²). Further eligibility criteria included being completely healthy and having a regular sleep wake rhythm. Participants were excluded if they had a history of or first-degree relatives with psychiatric or metabolic disorders. Individuals with current and/or a history of mental disorders as assessed by the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV axis I were excluded. Further exclusion criteria were significant abnormalities in laboratory or physical examinations, substance use (including any cigarette smoking within the last six months or abuse of alcohol or other illicit drugs), medication use during the past six months (except infrequent use of medication for pain (excluding opioids) until two weeks prior to the start of the study), high performance sport, shift work or time-zone travel in the previous 12 months. The full list of eligibility criteria may be obtained at http://clinicaltrials.gov/ct2/show/NCT00878540.

Current health status and past history were assessed by a detailed medical history, physical examination, routine blood draw (including complete blood count, liver, renal, and thyroid function and lipid profile) and urinalysis, electrocardiogram, electroencephalogram, and cranial magnetic resonance imaging (cMRI). The presence of a current and/or former psychiatric disorder according to DSM IV axis I was assessed with the modified version of the Munich-Composite International Diagnostic Interview (DIA-X/M-CIDI). [19] All study participants had a regular circadian rhythm without evidence of sleep disorders or daytime sleepiness as assessed with interviews, questionnaires, and sleep diaries (this has been comprehensively described previously). [20] Participants were recruited at the Max Planck Institute of Psychiatry, Munich, Germany between December 2008 and April 2010.

Assessments

Laboratory measurements

For lipid analysis, venous blood was drawn at 08.30 am after 12 hours of fasting from an antecubital vein using standard venipuncture techniques at baseline (i.e., morning of the first drug day) and after administration of mirtazapine for 7 days (i.e., morning after drug day 7). Blood samples were immediately processed. A standard lipid panel (TC, HDL-C, LDL-C and triglycerides) was done using an enzymatic assay (Roche Hitachi 912). Non-HDL-C and triglycerides to HDL-C ratio were calculated as follows: non-HDL-C=TC-HDL-C and triglycerides to HDL-C ratio=TG/HDL-C.

Other variables

Weight was measured in kilograms on a calibrated scale at 07.30 am after urination. BMI was calculated: BMI=kg/(m²). Waist and hip circumference were measured in cm with waist to hip ratio being the quotient of these measures.

Statistical analysis

Data were analyzed using the non-parametric paired sample two-sided Wilcoxon signed rank test. Results are reported as mean±SD or mean changes with 95% confidence intervals (CI) analyzed by paired t-tests. A significance level of α=5% was used for all tests. As all tests were hypothesis generating without confirmatory interpretation, no correction was applied to counteract the problem of multiple comparisons. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 25 and 28 (IBM Corp., Armonk, NY, USA).

Ethics

The study was approved by the local Ethics Committee of the Medical Faculty at the Ludwig Maximilians University, Munich, Germany and was carried out in accordance with the latest revision of the Declaration of Helsinki.

Baseline characteristics and weight, body composition and lipid profiles following the intervention are shown in Table 1.

Lipid metabolism

Triglycerides showed a statistically significant increase from 64±19.3 mg/dl at baseline to 68.4±17.4 mg/dl after administration of 30 mg mirtazapine for 7 days, (mean change +4.4;95% CI [-11.4, 2.6];p=0.044; Z=-2.01). Triglycerides increased in 10 of 12 participants and decreased in 2 of 12 individuals. HDL-C decreased from 47.5±5.6 mg/dl at baseline to 43.3±5.5 mg/dl at day seven (mean change -4.3;95% CI [2.1, 6.5];p=0.004;Z=-2.90). HDL-C decreased in 11 of 12 participants and increased in 1 of 12 participants. The TG/HDL-C ratio significantly increased from 1.4±0.4 mg/dl to 1.6±0.5 mg/dl (mean change +0.2;95% CI [-0.4, -0.1];p=0.019;Z=-2.35). TG/HDL-C ratio increased in 11 of 12 participants, and decreased in 1 of 12 participants. LDL-C decreased from 85.8±20.8 mg/dl at baseline to 77.2±17.2 mg/dl (mean change -8.7;95% CI [3.8, 13.5];p=0.008;Z=-2.65). LDL-C decreased in 9 of 12 participants, increased in 1 of 12 individuals and did not change in 2 of 12 participants. Non-HDL-C significantly decreased from 99±23.5 mg/dl to 91.1±19.4 mg/dl (mean change -8.0;95% CI [1.9, 14.0];p=0.023;Z=-2.28). A decrease in non-HDL-C was observed in 10 of 12 participants, in 2 of 12 non-HDL-C increased. Total cholesterol decreased from 146.6±25.1 mg/dl at baseline to 134.3±21.1 mg/dl at day seven (mean change -12.3;95% CI [5.4, 19.1];p=0.005;Z=-2.80). Total cholesterol decreased in 10 of 12 individuals, increased in 1 of 12 participants and remained unchanged in 1 of 12 participants.

Anthropometric measures

Body weight significantly decreased from 74.4 kg to 73.8 kg (mean change -0.6kg;95% CI [0.4, 0.8];p=0.002;Z=-3.1) and BMI significantly decreased from 22.8 to 22.6 (mean change -0.2;95% CI [0.1, 0.2];p=0.002;Z=-3.1). The decrease in body weight and BMI was very systematic and observed in all 12 participants. Waist circumference (mean change -0.4cm;95%CI[-2.1;2.9];p=0.838;Z=-.2) and waist-to-hip ratio (mean change 0.0;95% CI [-0.0, 0.0];p=0.814;Z=-.2) as a surrogate marker for central adiposity did not significantly change.

Main finding

This is the first analysis to report unfavorable changes in biomarkers for atherogenic dyslipidemia in healthy male participants in the context of weight loss following a seven-day administration of 30 mg/d mirtazapine. This observation is remarkable and provides insights into the short-term effects of mirtazapine on lipid metabolism that are independent of weight gain.

While weight gain and metabolic derangement are a well-described side effect of mirtazapine treatment in individuals with psychiatric disorders, [21] the effect of mirtazapine on lipid metabolism in healthy participants is less investigated. In healthy individuals, there is only one comparable study that investigated changes in lipid metabolism related to mirtazapine treatment. Nicholas and colleagues found that a four-week treatment with mirtazapine 15 mg per day, which was increased to 30 mg per day at the beginning of week two, resulted in a significant rise in plasma triglycerides and weight gain in 50 healthy individuals using a placebo-controlled study design. [7] Aligning with the observation of Nicholas et al., in our study, we observed a significant rise in triglycerides. However, contrary to their findings, triglycerides increased in our participants in the absence of weight gain. We observed a small but systematic weight loss in all participants. The reasons for the slight weight loss observed under dietary clamping and unchanged energy expenditure remains unclear. The expected effect of weight loss and loss of intrahepatic fat content in particular on the lipid profile, would be a decrease in serum triglyceride levels/triglyceride-rich lipoproteins. [22,23] However, despite a slight weight loss, triglycerides significantly increased in our study participants. While none of the healthy study participants met criteria for dyslipidemia after exposure to mirtazapine, these findings are of potential clinical importance for two major reasons. First, the changes became evident after a very short period on mirtazapine, raising concerns about long-term effects on lipid metabolism. This question about long-term effects of mirtazapine on blood lipid levels in the context of stable weight or weight loss cannot be addressed with this study but warrants further research. Second, and importantly, biomarkers of atherogenic dyslipidemia worsened in our study in the context of weight loss. It appears that effects of short-term exposure to mirtazapine outweigh the lipid changes that would be expected in the context of weight loss. [22,23] Taken together, our findings suggest potential effects of mirtazapine on hepatic lipid metabolism independent of weight gain.

The effects we observed in healthy individuals with short term exposure to mirtazapine may be more pronounced and of higher clinical relevance in individuals with depressive disorders with an elevated risk for metabolic disorders [24,25] and/or individuals with pre-existing metabolic conditions or prolonged treatment with mirtazapine. In addition, mirtazapine induced increases in appetite and cravings for sweet foods as reported previously [10] might result in weight gain under normal dietary conditions and add to drug-induced dyslipidemia. [26,27] This may overall contribute to elevation of cardiovascular risk in addition to cardiovascular risk already associated with psychiatric conditions such as major depression. [28]

Mechanistically, the effect of mirtazapine on triglyceride levels may in part be explained by disinhibition of insulin secretion by mirtazapine due to inhibition of pancreatic ß-cell α2-adrenoceptors. [17] As reported previously, as expected in the context of disinhibition of insulin secretion, we observed increased insulin release with mirtazapine in our study. [10] This aligns with the observed triglyceride increase since insulin stimulates hepatic de novo lipogenesis and VLDL-secretion [serum triglycerides can be considered as a surrogate for VLDL in this study (VLDL=triglycerides/5)]. [27,29,30] Furthermore, increased insulin and triglyceride levels and decreased HDL-C might account for our observation of a decrease in LDL-C after mirtazapine exposure potentially explained by this mechanism: a rise in TG/HDL-C ratio, as we observed in our analysis, implies compositional changes of LDL-particles due to a metabolic shift which renders LDL particles cholesterol-depleted and triglyceride-enriched. [27] This results in a decrease in LDL-C (i.e. lower LDL-cholesterol content). [27] TG/HDL-C ratio is a metabolic index that serves as a surrogate for atherogenic dyslipidemia, which encompasses a constellation of lipoprotein abnormalities including high serum triglycerides, low HDL-C and an atherogenic lipoprotein phenotype, including a predominance of small, cholesterol-depleted LDL-P, and an accumulation of triglyceride-rich lipoproteins. [27] Higher TG/HDL-C ratio (i.e. high triglycerides and low HDL-C) is associated with both insulin resistance and measures of atherogenic dyslipidemia, which includes a smaller LDL-P diameter, higher remnant lipoprotein particle cholesterol and further traits that render low density lipoproteins more atherogenic such as increased ApoC3. [27,31] In patients with coronary artery disease, the the TG/HDL-C ratio was significantly higher in patients with thin-cap fibroatheromas than in those without, and it was non-significantly higher in patients with multiple recurrent acute coronary syndromes than in those with long-standing stable angina. [32-34]

Overall, although our study included healthy individuals neither meeting the criteria for atherogenic dyslipidemia or hypertriglyceridemia, nor carrying any common vascular risk factors as documented by a thorough clinical assessment, we observed significant adverse short-term changes in lipoprotein pattern which may in part be explained by increased drug-induced insulin release as shown in our prior analysis. [10] Extrapolating these changes that occurred in a short period in healthy individuals, and considering the effects of mirtazapine on weight gain without caloric restriction, it is likely possible that these effects are clinically significant in the long run, i.e., under longer term antidepressant treatment and/or in the context of pre-existing metabolic conditions. [12,27] These alterations associated with mirtazapine exposure may have the potential to contribute to elevated cardiovascular risk with longer administration of the drug as it is common in treatment of individuals with depressive or anxiety disorders. Of note, in the context of pre-existing metabolic disorders as frequently observed as a comorbidity in psychiatric patients and in the absence of dietary restriction as in this study, [28] mirtazapine-related changes in lipid metabolism are likely even more pronounced. Additionally, mirtazapine induced appetite, and cravings for sweet foods in particular in our participants [10] that would have exacerbated drug-induced dyslipidemia mediated by weight gain and/or increased intrahepatic fat content under free-running conditions. [26,27]

Limitations and Strengths

Our analysis is limited to short-term effects of mirtazapine on lipid metabolism and additional research investigating long-term effects is warranted. Further, the small sample size and the lack of a placebo group limit interpretation and generalizability, and our results should be regarded as explorative and hypothesis-generating. Nevertheless, the highly standardized conditions and the use of an ‘extremely’ healthy and homogenous study population may be a first step towards disentangling the direct, weight-independent pharmacological effects of mirtazapine on lipid metabolism.

In conclusion, this is the first study showing unfavorable changes in lipid metabolism following a seven-day exposure to mirtazapine under highly standardized conditions in healthy participants and in the absence of weight gain. These findings support the hypothesis that alterations in lipid metabolism may be explained by primary pharmacological effects of mirtazapine independent of and in addition to known secondary effects associated with medication-induced weight gain. Due to the clinical relevance of these findings indicating potential contribution to cardiovascular risk further research is warranted including validation in larger cohorts or investigation of effects on lipid metabolism in individuals with mental health conditions where treatment with antidepressants is common such as depressive or anxiety disorders.

Clinical Perspectives

Competency in Patient Care

Our findings support the hypothesis that a direct pharmacological effect of mirtazapine may contribute to alterations in lipid metabolism independent of secondary effects related to medication-induced weight gain. Treatment with mirtazapine should be carefully considered in individuals at increased cardiometabolic risk and metabolic monitoring is advised.

Translational Outlook

Further research including metabolomics approaches may additionally improve our understanding of antidepressants’ effects on lipid metabolism and may eventually inform prediction of metabolic risk, monitoring strategies and individualized treatment.

Acknowledgements

Funding

Nothing to declare.

Authors’ contribution

JMH, SK, and SF designed the study. FH, LS, and SL supervised the study and contributed to the discussion. TD, SF, SH, JMH, SK, and KL collected data. KL analyzed data, did the literature search, and drafted the manuscript. MU provided laboratory analysis. All authors reviewed, edited, and approved the final version of the manuscript.

Acknowledgements

We are indebted Gabi Kohl, Katharina Mahler, Birte Balzer, Luise Vogl, Christine Zitzmann, Johannes Erdmann, Sylvia Tholl, and Margit Hausmann and the sleep lab team of the Max Planck Institute of Psychiatry for their valuable help in conducting the study. Work for this study was performed at the Max Planck Institute of Psychiatry and the Else Kröner Institute of Nutrition Medicine (Volker Schusdziarra), both in Munich, Germany. We furthermore thank all individuals for participating in this study.

Conflict of Interest

KL, SH, MU, TD, SL, LS, SF, SK and JMH have no conflict to declare with respect to this manuscript. FH is cofounder of the biotech company HolsboerMaschmeyerNeuroChemie GmbH (HMNC GmbH) in Germany. FH and MU are co-inventors on the following patent applications: “FKBP5: a novel target for antidepressant therapy” (international application number WO 2005/054500) and “Polymorphisms in ABCB1 associated with a lack of clinical response to medicaments” (international application number PCT/ EP2005/005194).

Croom KF, Perry CM, Plosker GL (2009) Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs 23:427–452
De Boer T, Nefkens F, Van Helvoirt A (1994) The alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 253:R5–6
Puzantian T (1998) Mirtazapine, an antidepressant. Am J Health-Syst Pharm 55:44–49
Gartlehner G, Thieda P, Hansen RA et al (2008) Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 31:851–865
Himmerich H, Fulda S, Schaaf L et al (2006) Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 29:170
Kraus T, Haack M, Schuld A et al (2002) Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 35:220–225
Nicholas LM, Ford AL, Esposito SM et al (2003) The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 64:883–889
Watanabe N, Omori IM, Nakagawa A et al (2010) Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 24:35–53
Zimmermann U, Kraus T, Himmerich H et al (2003) Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 37:193–220
Hennings JM, Heel S, Lechner K et al (2019) Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men.JCI insight; 4
Roose SP (2003) Compliance: the impact of adverse events and tolerability on the physician's treatment decisions. Eur Neuropsychopharmacol 13(Suppl 3):S85–92
Ganda OP, Bhatt DL, Mason RP et al (2018) Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. J Am Coll Cardiol 72:330–343
McIntyre RS, Park KY, Law CWY et al (2010) The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 24:741–753
McIntyre RS, Soczynska JK, Konarski JZ et al (2006) The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 5:523–537
Fisfalen ME, Hsiung RC (2003) Glucose dysregulation and mirtazapine-induced weight gain. Am J Psychiatry 160:797
Hennings JM, Ising M, Grautoff S et al (2010) Glucose tolerance in depressed inpatients, under treatment with mirtazapine and in healthy controls. Experimental and clinical endocrinology & diabetes: official journal. German Soc Endocrinol [and] German Diabetes Association 118:98–100
Hennings JM, Schaaf L, Fulda S (2012) Glucose metabolism and antidepressant medication. Curr Pharm Design 18:5900–5919
Kopf D, Westphal S, Luley CW et al (2004) Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. J Clin Psychopharmacol 24:527–531
Wittchen HU, Lachner G, Wunderlich U et al (1998) Test-retest reliability of the computerized DSM-IV version of the Munich-Composite International Diagnostic Interview (M-CIDI). Soc Psychiatry Psychiatr Epidemiol 33:568–578
Fulda S, Kloiber S, Dose T et al (2013) Mirtazapine Provokes Periodic Leg Movements during Sleep in Young Healthy Men. Sleep 36:661–669
Himmerich H, Minkwitz J, Kirkby KC (2015) ; 15: 252–260
Chan DC, Watts GF, Ng TW et al (2008) Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Eur J Clin Invest 38:743–751
Borén J, Chapman MJ, Krauss RM et al (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 41:2313–2330
Vancampfort D, Stubbs B, Mitchell AJ et al (2015) Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World psychiatry: official journal of the World Psychiatric Association (WPA) 14:339–347
Pan A, Keum N, Okereke OI et al (2012) Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 35:1171–1180
Hieronimus B, Stanhope KL (2020) Dietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII. Curr Opin Lipidol 31:20–26
Lechner K, McKenzie AL, Kränkel N et al (2020) High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. Metab Syndr Relat Disord 18:176–185
Penninx B, Lange SMM (2018) Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialog Clin Neurosci 20:63–73
Titchenell PM, Quinn WJ, Lu M et al (2016) Direct Hepatocyte Insulin Signaling Is Required for Lipogenesis but Is Dispensable for the Suppression of Glucose Production. Cell Metabol 23:1154–1166
Samuel VT, Shulman GI (2016) The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 126:12–22
Arnold N, Lechner K, Waldeyer C et al (2021) Inflamm Cardiovasc Disease: Future Eur Cardiol 16:e20
Lechner K, Halle M (2019) Are Atherogenic Lipoprotein Phenotype and Inflammation Indicative of Plaque Phenotype and Clinical Stability in Coronary Artery Disease? JAMA Cardiol 4:950–951
Vergallo R, Porto I, Crea F (2019) Are Atherogenic Lipoprotein Phenotype and Inflammation Indicative of Plaque Phenotype and Clinical Stability in Coronary Artery Disease?—Reply. JAMA Cardiol 4:951–952
Vergallo R, Porto I, D'Amario D et al (2019) Coronary Atherosclerotic Phenotype and Plaque Healing in Patients With Recurrent Acute Coronary Syndromes Compared With Patients With Long-term Clinical Stability: An In Vivo Optical Coherence Tomography Study. JAMA Cardiol 4:321–329

Table 1. Baseline characteristics and weight, waist circumference and lipid profiles at baseline and following the intervention^A

	Baseline		Post-intervention		Z	P^B	Mean change	95% CI
	M	SD	M	SD
Age (years)	22.3	1.5
Height (cm)	180.7	6.9
Weight (kg)	74.4	5.9	73.8	5.8	-3.1	0.002	-0.6	0.4;0.8
Body-mass-index (kg/m²)	22.8	1.6	22.6	1.6	-3.1	0.002	-0.2	0.1;0.2
Waist circumference (cm)	78.9	4.2	78.5	2.9	-.2	0.838	-0.4	-2.1;2.9
Waist/hip ratio	0.9	0.0	0.9	0.0	-.2	0.814	0.0	-0.0;0.0
Total cholesterol (mg/dl)	146.6	25.1	134.3	21.1	-2.8	0.005	-12.3	5.4;19.1
Triglycerides (mg/dl)	64	19.3	68.4	17.4	-2	0.044	4.4	-11.4;2.6
HDL-C (mg/dl)	47.5	5.6	43.3	5.5	-2.9	0.004	-4.3	2.1;6.5
LDL-C (mg/dl)	85.8	20.8	77.2	17.2	-2.7	0.008	-8.7	3.8;13.5
Non-HDL-C (mg/dl)	99	23.4	91.1	19.4	-2.3	0.023	-8.0	1.9;14.0
TG/HDL-C (mg/dl)	1.4	0.4	1.6	0.5	-2.4	0.019	0.2	-0.4;0.1

^AData (n = 12) are mean values (M) and standard deviations (SD)

^B two-sided significance P < 0.05 is in bold (two-sided Wilcoxon signed rank test)

Download PDF

Version 1

posted

You are reading this latest preprint version

Weight-gain Independent Effect of Mirtazapine on Fasting Plasma Lipids in Healthy Men

Status:

Version 1

Abstract

Figures

Introduction

Methods

Study Design

Study population

Assessments

Laboratory measurements

Statistical analysis

Results

Discussion

Conclusion

Declarations

References

Table

Status:

Version 1